IDEXX Laboratories Inc. (IDXX) Stock
NASDAQIDXX has an Alpha Score of 44 out of 100 (weak), computed on Oct 26, 2026 from 3 of 4 sub-scores. 8 members of Congress disclosed 24 trades in IDXX since 2014: 11 purchases and 13 sales, most recently April McClain Delaney (sale, Jan 13, 2026). 7 of the hedge funds AlphaScala tracks reported IDXX in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Fundsmith's at $536.91M. Company insiders reported 0 open-market buys and 1 sale on SEC Form 4 in the 90 days to Oct 30, 2026. Its trailing P/E ratio is 38.9 and its net margin 25.0% (key statistics as of Oct 29, 2026).
What is IDXX's Alpha Score?
How it works →Alpha Score of 44 reflects weak overall profile with weak momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Oct 26, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded IDEXX Laboratories Inc. (IDXX)?
Most recent: April McClain Delaney (sale, Jan 13, 2026); records start Mar 11, 2014.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| April McClain Delaney D-MD · House | 2026-01-13 | sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-12-02 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-10-29 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-10-16 | partial sale | $1k – $15k |
| Byron Donalds R-FL · House | 2025-09-04 | purchase | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-08-07 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-08-01 | partial sale | $1k – $15k |
| April McClain Delaney D-MD · House | 2025-07-09 | partial sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 29, 2026.
See all IDXX political trades →Which hedge funds own IDXX?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Fundsmith Terry Smith | 1.02M | $536.91M | -30% |
| Point72 Steve Cohen | 263K | $138.40M | +103% |
| Renaissance Technologies Jim Simons (founder) | 110K | $57.79M | +126% |
| Marshall Wace | 93K | $49.03M | +89% |
| Millennium Management Israel Englander | 79K | $41.58M | +12% |
| Citadel Ken Griffin | 39K | $20.45M | -56% |
| Bridgewater Associates Ray Dalio | 34K | $17.65M | +225% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are IDEXX Laboratories Inc. insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Sep 4, 26 | Kingsley Lawrence D | Director | SELL | 2.2K | $1.2M |
| Mar 3, 26 | Hunt Nimrata | Executive Vice President | SELL | 1.8K | $1.1M |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.3K | $834K |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.1K | $713K |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.7K | $1.1M |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.2K | $765K |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.1K | $727K |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.5K | $976K |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 1.3K | $882K |
| Feb 26, 26 | Mazelsky Jonathan Jay | President and CEO | SELL | 2.9K | $1.9M |
SEC Form 4 filings as of Oct 30, 2026
See cluster-buy signals across all tickers →What are IDXX's key statistics?
Key statistics as of Oct 29, 2026
How does IDXX's valuation compare with the Healthcare sector?
| Metric | IDXX | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 38.9 | 27.1 | 97 |
| Net margin | 25.03% | 5.48% | 139 |
| Return on equity | 71.96% | 6.84% | 158 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 2, 2026). P/E excludes loss-making companies.
IDXX price chart
Powered by TradingViewWhat does IDEXX Laboratories Inc. do?
IDEXX Laboratories, Inc. is an American multinational corporation that develops, manufactures, and distributes diagnostic products and services for veterinary and environmental markets. The company specializes in solutions for companion animal health, including in-clinic laboratory analyzers like the Catalyst Dx Chemistry Analyzer and ProCyte Dx Hematology Analyzer, pet-side SNAP tests, diagnostic imaging systems, and veterinary practice management software such as Cornerstone. It also offers water testing products like Colilert for detecting coliforms and E. coli, alongside diagnostics for livestock, poultry, and dairy to monitor diseases in herds and flocks, as well as milk quality. Additionally, IDEXX provides point-of-care and laboratory diagnostics through OPTI Medical Systems for human medicine. These offerings support veterinarians, water utilities, livestock producers, and reference laboratories worldwide, enhancing health monitoring and safety in pet care, agriculture, and public health. Founded in 1983 and headquartered in Westbrook, Maine, IDEXX Laboratories, Inc. plays a key role in advancing diagnostic innovation across these essential sectors.